Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The firm focuses on the medication of genetically defined cardiovascular diseases and sub-group of Alzheimer’s disease. It offers LX2006 for the treatment of patients with Friedreich's ataxia, cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer's disease. The company was founded by Ronald G. Crystal in February 2017 and is headquartered in New York, NY.
相关临床试验
8
4 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2018
进行中（未招募）
3
37.5%
已完成
1
12.5%
Enrolling By Invitation
1
12.5%
招募中
3
37.5%
暂无批准数据
- Mana.bio has appointed Dr. Laura Sepp-Lorenzino, former CSO of Intellia Therapeutics, to its Scientific Advisory Board to guide the company's AI-driven LNP discovery platform. - Dr. Sepp-Lorenzino brings decades of leadership experience from Intellia, Vertex Pharmaceuticals, Alnylam, and Merck, spanning CRISPR, RNAi, and nucleic acid therapies. - Mana.bio's proprietary AI/ML platform leverages the world's largest curated LNP dataset to predict safety, tropism, and stability, with NHP-validated delivery solutions for extrahepatic targets. - The appointment comes at what CEO Yogev Debbi describes as a pivotal stage of growth as the company scales its discovery engine and expands its therapeutic pipeline.
- An experimental AAV-based gene therapy delivering a healthy frataxin gene was well tolerated in a pooled phase 1 trial of 17 patients with Friedreich ataxia cardiomyopathy. - Cardiac frataxin protein levels increased in all eight biopsied patients, with dose-dependent rises of 20% to 123% across cohorts. - Left ventricular mass index decreased by at least 10% in nine patients and stabilized in eight, while troponin I levels dropped in 15 of 17 patients. - The findings, published in JAMA Cardiology, represent the first human evidence that gene therapy may address the cardiac manifestations of this fatal inherited disease.
- UC San Diego researchers discovered that restoring connexin-43 protein through gene therapy more than doubled lifespan and dramatically improved heart function in mouse models of arrhythmogenic cardiomyopathy. - The therapy showed effectiveness across multiple genetic forms of ACM by addressing a common downstream defect, potentially offering a universal treatment approach for this leading cause of sudden cardiac death in young athletes. - LEXEO Therapeutics has acquired the connexin-43 program for commercial development, with preclinical studies underway to evaluate safety and therapeutic potential. - The approach also demonstrated efficacy in human heart muscle cells derived from ACM patients, suggesting broader therapeutic applications for various forms of cardiomyopathy and heart failure.
- Lexeo Therapeutics announced positive interim Phase I/II data for LX2020, an AAV-based gene therapy for PKP2-associated arrhythmogenic cardiomyopathy affecting approximately 60,000 Americans. - The therapy demonstrated dose-dependent increases in PKP2 protein expression, with 93% increase in low-dose cohort and 162% increase in high-dose cohorts, alongside improved arrhythmia burden in majority of participants. - LX2020 was generally well tolerated across ten participants with no clinically significant complement activation, though five participants experienced manageable liver function test elevations at high doses. - The company plans regulatory engagement in 2026 and expects 12-month data for all high-dose participants by Q4 2026.
- Lexeo Therapeutics has announced a research collaboration with Johnson & Johnson to investigate localized cardiac delivery of gene therapy using Impella heart pump technology. - The partnership aims to concentrate AAV delivery to the heart through cutting-edge administration routes, potentially reducing required doses and improving safety while maximizing therapeutic efficacy. - The collaboration combines Lexeo's expertise in cardiac genetic medicine with Johnson & Johnson's cardiovascular therapeutics capabilities to advance treatments for genetically mediated cardiovascular diseases. - Impella heart pumps provide direct cardiac unloading to enhance myocardial perfusion, which may facilitate improved gene therapy delivery to cardiac tissue.
- Health Secretary Robert F. Kennedy Jr. announced plans to fast-track FDA approvals for rare disease treatments and remove regulatory obstacles during a meeting focused on cell and gene therapies. - FDA's new biologics chief Vinay Prasad committed to rapidly making therapies available at the first sign of biomedical success, addressing industry concerns about regulatory barriers. - Panel experts warned that slower US approval processes risk losing biotechnology leadership to countries like China, potentially forcing companies to relocate trials overseas. - Biotech stocks responded positively, with therapy developers seeing gains of 1-8% following the regulatory reform announcements.
- Lexeo Therapeutics raised $80 million in private placement financing led by Frazier Life Sciences and Janus Henderson Investors to advance its genetic medicine pipeline for cardiovascular diseases. - The funding extends the company's cash runway into 2028 and will support operations through the potential 2027 efficacy readout for LX2006 in Friedreich ataxia cardiomyopathy. - The clinical-stage company is developing therapeutic candidates targeting genetic causes of cardiovascular conditions, including LX2006 for Friedreich ataxia cardiomyopathy and LX2020 for plakophilin-2 arrhythmogenic cardiomyopathy.
- Leap Therapeutics has announced a significant restructuring, reducing its workforce by approximately 50% and narrowing the development focus of its lead cancer drug candidate in response to challenging market conditions. - The strategic pivot aims to extend the company's cash runway while concentrating resources on the most promising clinical applications of its lead oncology asset, potentially improving its chances for regulatory success. - This move follows similar restructuring trends across the biotech sector, with companies like Arcturus, NGM Bio, and Erasca all recently announcing staff reductions and pipeline reprioritizations to navigate the difficult funding environment.
- Lexeo Therapeutics will present new data on its optimized Sf9-baculovirus manufacturing process for AAV gene therapy vectors at the upcoming ASGCT Annual Meeting in New Orleans. - The company's platform demonstrates improved scalability and cost-efficiency while maintaining high purity and potency, potentially accelerating development timelines for clinical-stage gene therapy programs. - Two poster presentations will highlight advancements in VP1 ratio optimization and a novel high-yielding process capable of producing quality AAV vectors at 200L scale.
• Dyne Therapeutics has appointed Vikram Ranade, PhD, as Chief Business Officer and Ranjan Batra, PhD, as Chief Scientific Officer, bolstering its executive team ahead of potential product launches in 2027. • Dr. Batra, an RNA biology expert with experience developing therapies for rare neuromuscular disorders, will lead research strategy and pipeline development for Dyne's FORCE™ platform technology. • Current CSO Oxana Beskrovnaya, PhD, will transition to Chief Innovation Officer, focusing on maximizing the potential of Dyne's TfR1 delivery platform for new therapeutic applications in neuromuscular diseases.
